JODI RENIGAR: Open Payments
NPI 1447949383 · WYNNE, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$270 in 17 payments from 9 companies in 2025. Trend: 2023 $275 · 2024 $718 · 2025 $270
Food & beverage: $270
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $61 |
| ABBVIE INC. | 3 | $58 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $30 |
| Exact Sciences Corporation | 2 | $30 |
| Phathom Pharmaceuticals, Inc. | 2 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Medtronic, Inc. | 1 | $18 |
| GlaxoSmithKline, LLC. | 1 | $15 |
| AstraZeneca Pharmaceuticals LP | 1 | $14 |
Products named: CAPLYTA, Ozempic, QULIPTA, VOQUEZNA, GVOKE HYPOPEN, MINIMED 780G, VRAYLAR, Wegovy.
Industry payments across AR — which companies pay providers there.
